Abstract
A biologics license application (BLA) for sotatercept, a therapeutic agent targeting activin receptor signaling implicated in pulmonary arterial hypertension (PAH), has been granted priority review status by the FDA. This advancement underscores the critical need for novel pharmacological interventions for this rare and severe condition, potentially transforming the therapeutic landscape of PAH.